DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration

DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration

Collaboration Will Focus on Development of Novel Diagnostic Tests for Dialysis
Patients

SALT LAKE CITY, June 17, 2013 (GLOBE NEWSWIRE) -- DaVita Labs, a unit of
DaVita HealthCare Partners Inc. (NYSE:DVA) and Myriad RBM, a wholly-owned
subsidiary of Myriad Genetics (Nasdaq:MYGN) announced today a research
collaboration to conduct protein biomarker discovery research with the goal of
developing and commercializing diagnostic tests that could benefit in the
treatment of dialysis patients.

DaVita and Myriad have identified potential opportunities where novel
diagnostic tests utilizing blood-based protein biomarkers could improve the
quality of life for patients and potentially lower overall healthcare costs.
The primary area of focus will include the prediction of vascular access
failure.

"This collaboration uses DaVita's proprietary biorepository that is intended
to facilitate innovative research across renal disease," said Chris Rucker,
president of DaVita Labs and DaVita Clinical Research. "Myriad recognizes the
value that the biorepository can bring to research and development activities,
and we look forward to collaborating with Myriad on the research and
development of novel diagnostics that could transform our industry."

"We are enthusiastic to collaborate with a company of the caliber of DaVita in
the field of dialysis, one of the largest health care service markets," said
Craig Benson, president Myriad RBM. "We have extensive experience with
research in kidney disease and inflammatory markers that we believe could
increase the quality of care for dialysis patients."

Specimens from the DaVita biorepository will be processed on the Myriad RBM
DiscoveryMAP^® platform for the quantification of more than 300 important
proteins. DiscoveryMAP analyzes protein biomarkers correlated with
inflammatory, metabolic and renal disease conditions that could have
meaningful utility as diagnostic criteria for dialysis patients. Myriad is
expected to begin processing specimens associated with this collaboration in
fiscal year 2014.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making
a difference in patients' lives through the discovery and commercialization of
transformative tests to assess a person's risk of developing disease, guide
treatment decisions and assess risk of disease progression and recurrence.
Myriad's portfolio of molecular diagnostic tests are based on an understanding
of the role genes play in human disease and were developed with a commitment
to improving an individual's decision making process for monitoring and
treating disease. Myriad is focused on strategic directives to introduce new
products, including companion diagnostics, as well as expanding
internationally. For more information on how Myriad is making a difference,
please visit the Company's website: www.myriad.com.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune
500® company that, through its operating divisions, provides a variety of
health care services to patient populations throughout the United States and
abroad. A leading provider of kidney care in the United States, DaVita
delivers dialysis services to patients with chronic kidney failure and end
stage renal disease. DaVita strives to improve patients' quality of life by
innovating clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services. As of March
31, 2013, DaVita operated or provided administrative services at 1,991
outpatient dialysis centers located in the United States serving approximately
156,000 patients. The company also operated 41 outpatient dialysis centers
located in nine countries outside the United States. DaVita supports numerous
programs dedicated to creating positive, sustainable change in communities
around the world. The company's leadership development initiatives and social
responsibility efforts have been recognized by Fortune, Modern Healthcare,
Newsweek and WorldBlu. For more information, please visit DaVita.com.

Myriad and the Myriad logo are trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the announced research collaboration to conduct protein biomarker
discovery research with the goal of developing and commercializing diagnostic
tests that could benefit in the treatment of dialysis patients; and the
Company's strategic directives under the caption "About Myriad Genetics".
These "forward-looking statements" are management's present expectations of
future events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from those
described in the forward-looking statements. These risks include, but are not
limited to: the risk that sales and profit margins of our existing molecular
diagnostic tests and companion diagnostic services may decline or will not
continue to increase at historical rates; risks related to changes in the
governmental or private insurers reimbursement levels for our tests; the risk
that we may be unable to develop or achieve commercial success for additional
molecular diagnostic tests and companion diagnostic services in a timely
manner, or at all; the risk that we may not successfully develop new markets
for our molecular diagnostic tests and companion diagnostic services,
including our ability to successfully generate revenue outside the United
States; the risk that licenses to the technology underlying our molecular
diagnostic tests and companion diagnostic services tests and any future tests
are terminated or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general or our
tests in particular; risks related to regulatory requirements or enforcement
in the United States and foreign countries and changes in the structure of the
healthcare system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks related to
our ability to successfully integrate and derive benefits from any
technologies or businesses that we license or acquire; the development of
competing tests and services; the risk that we or our licensors may be unable
to protect the proprietary technologies underlying our tests; the risk of
patent-infringement claims or challenges to the validity of our patents; risks
of new, changing and competitive technologies and regulations in the United
States and internationally; and other factors discussed under the heading
"Risk Factors" contained in Item 1A in our most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, as well as any updates
to those risk factors filed from time to time in our Quarterly Reports on Form
10-Q or Current Reports on Form 8-K. All information in this press release is
as of the date of the release, and Myriad undertakes no duty to update this
information unless required by law.

CONTACT: DaVita Contacts
         Media: Bianca Violante
         (303) 876-6614
         bianca.violante@davita.com
        
         Investors: Jim Gustafson
         (310) 536-2585
         jim.gustafson@davita.com
        
         Myriad Genetics Contacts
         Media: Ron Rogers
         (801) 584-3065
         rrogers@myriad.com
        
         Investors: Scott Gleason
         (801) 584-1143
         sgleason@myriad.com
 
Press spacebar to pause and continue. Press esc to stop.